Healthcare tech company Omnicell (NASDAQ: OMCL) will be announcing earnings results this Thursday morning. Here’s what you need to know.

Omnicell beat analysts’ revenue expectations by 4.9% last quarter, reporting revenues of $290.6 million, up 5% year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates.

Is Omnicell a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Omnicell’s revenue to grow 4.7% year on year to $295.8 million, a reversal from the 5.4% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.36 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Omnicell has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 3.3% on average.

With Omnicell being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for healthcare technology stocks. However, there has been positive investor sentiment in the segment, with share prices up 6.1% on average over the last month. Omnicell is down 1.3% during the same time and is heading into earnings with an average analyst price target of $44 (compared to the current share price of $29.94).

P.S. While everyone's chasing Nvidia, we found a hidden AI semiconductor winner trading at a fraction of the price. See our #1 pick before Wall Street catches on.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.